Trung Huynh
Stock Analyst
(4.64)
# 4,648
Out of 4,648 analysts
30
Total ratings
65.22%
Success rate
24.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $5.16 | +151.94% | 1 | Oct 10, 2024 | |
| CABA Cabaletta Bio | Initiates: Buy | $10 | $4.00 | +150.00% | 1 | Oct 10, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $54 | $55.45 | -2.61% | 4 | Oct 9, 2024 | |
| INSM Insmed | Maintains: Buy | $78 → $84 | $68.09 | +23.37% | 3 | Aug 9, 2024 | |
| LLY Eli Lilly | Assumes: Buy | $612 → $710 | $806.14 | -11.93% | 7 | Oct 20, 2023 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $170 → $175 | $158.24 | +10.59% | 2 | Jul 21, 2023 | |
| AMGN Amgen | Maintains: Outperform | $220 → $200 | $316.91 | -36.89% | 3 | Jul 12, 2023 | |
| PFE Pfizer | Downgrades: Neutral | $47 → $40 | $27.76 | +44.09% | 4 | Jun 29, 2023 | |
| MRK Merck & Co. | Maintains: Outperform | $125 → $126 | $101.87 | +23.69% | 3 | Mar 7, 2023 | |
| ABBV AbbVie | Initiates: Outperform | $170 | $200.47 | -15.20% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.80 | - | 1 | Mar 23, 2021 |
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $5.16
Upside: +151.94%
Cabaletta Bio
Oct 10, 2024
Initiates: Buy
Price Target: $10
Current: $4.00
Upside: +150.00%
Bristol-Myers Squibb Company
Oct 9, 2024
Maintains: Neutral
Price Target: $50 → $54
Current: $55.45
Upside: -2.61%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $78 → $84
Current: $68.09
Upside: +23.37%
Eli Lilly
Oct 20, 2023
Assumes: Buy
Price Target: $612 → $710
Current: $806.14
Upside: -11.93%
Johnson & Johnson
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $158.24
Upside: +10.59%
Amgen
Jul 12, 2023
Maintains: Outperform
Price Target: $220 → $200
Current: $316.91
Upside: -36.89%
Pfizer
Jun 29, 2023
Downgrades: Neutral
Price Target: $47 → $40
Current: $27.76
Upside: +44.09%
Merck & Co.
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $101.87
Upside: +23.69%
AbbVie
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $200.47
Upside: -15.20%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $8.80
Upside: -